肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2021-07-28 yd2015 MedSci原创

阿替利珠单抗（Atezolizumab）恶性腹膜间皮瘤（MPeM）贝伐珠单抗（bevacizumab）
关注

阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）具有良好的应答以及耐受性，值得进一步的探索。

恶性腹膜间皮瘤（MPeM）是一种罕见的恶性肿瘤，发病率为0·11/100,000，但是恶性程度较高，5年生存低于20%。对于MPeM的治疗，大多数来源于恶性胸膜间皮瘤的治疗或是回顾性研究。目前NCCN治疗推荐培美曲塞联合铂类一线治疗恶性腹膜间皮瘤，但是一线治疗进展后的选择很少。50-60%的MPeM患者表达PD-L1。而且目前免疫检查点抑制剂对恶性胸膜间皮瘤有一定的疗效。因此，有团队开展研究评估PD-L1抑制剂阿替利珠单抗（atezolizumab）联合抗血管贝伐珠单抗（bevacizumab）在恶性腹膜间皮瘤（MPeM）的疗效，相关结果发表在Cancer Discovery杂志上。 研究纳入20例患者，中位年龄63岁，60%为女性，75%患者否认石棉暴露史。其中12例患者(60%)既往除了全身化疗外，还进行了肿瘤减瘤术（CRS）和腹腔热灌注化疗（HIPEC）。所有患者之前都接受过铂联合培美曲塞治疗(只有1例患者之前接受过贝伐单抗)，8例(40%)患者在入组前接受过2种治疗。其中17例(85%)患者有疾病进展，3例(15%)不能耐受铂联合培美曲塞治疗。 数据截止时，中位随访23.5个月

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-08-07 cmj8wellington

    #Dis#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-05-17 Demon9190

    👍🏻

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-01-08 soongzhihua

    #MPE#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-05-19 仁医06

    #贝伐珠#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-05-27 snf701207

    #mAb#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-03-05 feather89

    #PE#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-08-18 ms1779634646866130

    #替利珠单抗#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-11-05 nymo

    #腹膜间皮瘤#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-30 sunrural_42825359

    #贝伐#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2013666, encodeId=3af5201366651, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 07 21:00:09 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220256, encodeId=616b12202563f, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/08/742c3d822ad9fd88e02ab3d577dada13.jpg, createdBy=48025202780, createdName=Demon9190, createdTime=Tue May 17 11:20:39 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12171, encryptionId=90e9121e19f, topicName=MPE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Sat Jan 08 07:00:09 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu May 19 10:00:09 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912660, encodeId=7587191266090, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri May 27 22:00:09 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729056, encodeId=51561e290561f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Mar 05 09:00:09 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60335, encryptionId=f1dc603355d, topicName=替利珠单抗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Wed Aug 18 20:00:09 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010658, encodeId=283d20106586a, content=<a href='/topic/show?id=271185668ef' target=_blank style='color:#2F92EE;'>#腹膜间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85668, encryptionId=271185668ef, topicName=腹膜间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Nov 05 12:00:09 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477085, encodeId=1f0814e708551, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579831, encodeId=452615e9831da, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Fri Jul 30 09:00:09 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-30 1249884fm92暂无昵称

    #间皮瘤#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

现有证据不支持阿替利珠单抗（Atezolizumab）加入初始诊断FIGO III或IV期卵巢癌的标准治疗中。

Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析

atezolizumab联合紫杉醇对比紫杉醇单药并不能改善不可切除、局部晚期或转移性三阴性乳腺癌(TNBC)患者的PFS或OS。

J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150

IMpower150研究发现，ACP组较BCP组在数值上改善患者的OS，但没有统计学差异；而更新的OS分析表明ABCP较BCP持续改善患者的OS。